Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
70
EBS Quote, Financials, Valuation and Earnings
Last price:
$12.43
Seasonality move
:
-2.41%
Day range:
$12.51 - $12.86
52-week range:
$4.02 - $13.41
Dividend yield:
0%
P/E ratio:
9.76x
P/S ratio:
0.89x
P/B ratio:
1.14x
Volume:
322K
Avg. volume:
851.7K
1-year change:
52.17%
Market cap:
$663.3M
Revenue:
$1B
EPS (TTM):
$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$199M | -$0.12 | 11.71% | -94.67% | $13.50 |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-- | -$0.23 | -100% | -39.8% | $9.25 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$12.63 | $13.50 | $663.3M | 9.76x | $0.00 | 0% | 0.89x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
$2.67 | $9.25 | $152.1M | 7.36x | $0.00 | 0% | 2.17x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.454 | 144.36% | 2.93x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
13.49% | 4.929 | 9.11% | 8.72x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-$86K | -$11M | 15.62% | 18.5% | 77.9% | -$7.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Emergent BioSolutions, Inc. vs. Competitors
-
Which has Higher Returns EBS or BDTX?
Black Diamond Therapeutics, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 80.77%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Black Diamond Therapeutics, Inc.'s return on equity of 18.5%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M -
What do Analysts Say About EBS or BDTX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 6.89%. On the other hand Black Diamond Therapeutics, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 253.13%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 BDTXBlack Diamond Therapeutics, Inc.6 1 0 -
Is EBS or BDTX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Black Diamond Therapeutics, Inc. has a beta of 3.331, suggesting its more volatile than the S&P 500 by 233.083%.
-
Which is a Better Dividend Stock EBS or BDTX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Black Diamond Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Black Diamond Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or BDTX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Black Diamond Therapeutics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Black Diamond Therapeutics, Inc.'s net income of -$8.5M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 9.76x while Black Diamond Therapeutics, Inc.'s PE ratio is 7.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.89x versus 2.17x for Black Diamond Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.89x 9.76x $231.1M $51.2M BDTXBlack Diamond Therapeutics, Inc.2.17x 7.36x -- -$8.5M
-
Which has Higher Returns EBS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of -255.85%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About EBS or NBY?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 6.89%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Emergent BioSolutions, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is EBS or NBY More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock EBS or NBY?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or NBY?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 9.76x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.89x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.89x 9.76x $231.1M $51.2M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns EBS or OGEN?
Oragenics, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About EBS or OGEN?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 6.89%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Oragenics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is EBS or OGEN More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock EBS or OGEN?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or OGEN?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Oragenics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 9.76x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.89x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.89x 9.76x $231.1M $51.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns EBS or PTN?
Palatin Technologies has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B PTNPalatin Technologies-- -- -- -
What do Analysts Say About EBS or PTN?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 6.89%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Emergent BioSolutions, Inc., analysts believe Palatin Technologies is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is EBS or PTN More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock EBS or PTN?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or PTN?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Palatin Technologies quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Palatin Technologies's net income of --. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 9.76x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.89x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.89x 9.76x $231.1M $51.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns EBS or TOVX?
Theriva Biologics, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About EBS or TOVX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 6.89%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is EBS or TOVX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.318, which suggesting that the stock is 131.831% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock EBS or TOVX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or TOVX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 9.76x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.89x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.89x 9.76x $231.1M $51.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
